It was earlier reported that the AstraZeneca Covid-19 vaccine trial was on hold over safety concern.
To elaborate, discussions about early authorizations and reports about White House pressure to speed along a coronavirus vaccine have worried the public.
The latest reports that Drug giant AstraZeneca said Tuesday it had paused global trials of its coronavirus vaccine because of unexplained illness in one of the volunteers is a real spanner in the works for risk appetite.
The company is testing its vaccine, called the Oxford vaccine which markets had high hopes for.
However, the hold up vs the concerns about moving too fast is a cocktail of contradictions which is concerning on both sides of the coin.
Earlier Tuesday, AstraZeneca joined eight other companies in signing a pledge promising they would not seek premature government approval for any coronavirus vaccine which could help to alleviate concerns to an extent.
"We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles," a statement read that was signed by the CEOs of AstraZeneca, BioNTech GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi.
"We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved," they added.
Nevertheless, with the stock market in a rout and risk assets struggling, this vaccine news is another problematic area for markets to recover from and we are indeed seeing downside in Asia today.
Market update since the news
The Nikkei is down some 1.5%.
Australian stocks that had kicked off Wednesday in the negative zone, pulled down by the US equities, is now down over 2%.
The Hang Seng Index is down over 1% and the SSE Composite is down over 1% also.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.